Profile data is unavailable for this security.
About the company
CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. It is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its neflamapimod is in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies and early Alzheimer’s disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke. Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in dementia with Lewy bodies (DLB) and certain other neurological disorders. It is being evaluated in its ongoing RewinD-LB Trial, a Phase 2b study in patients with DLB.
- Revenue in USD (TTM)9.65m
- Net income in USD-5.04m
- Incorporated2015
- Employees8.00
- LocationCervoMed Inc20 Park Plaza, Suite 424BOSTON 02116United StatesUSA
- Phone+1 (617) 744-4400
- Fax+1 (434) 220-0722
- Websitehttps://cervomed.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Relmada Therapeutics Inc | 0.00 | -86.76m | 98.97m | 20.00 | -- | 1.61 | -- | -- | -2.88 | -2.88 | 0.00 | 2.04 | 0.00 | -- | -- | 0.00 | -89.88 | -- | -100.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| MDxHealth SA | 80.74m | -40.80m | 100.48m | 300.00 | -- | -- | -- | 1.24 | -1.54 | -1.54 | 3.06 | -0.3229 | 0.5906 | 9.39 | 7.49 | 269,136.70 | -29.85 | -51.62 | -43.63 | -64.72 | 62.64 | 50.88 | -50.54 | -117.64 | 0.8252 | -1.74 | 1.18 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| Werewolf Therapeutics Inc | 9.28m | -53.73m | 100.51m | 45.00 | -- | 0.9663 | -- | 10.83 | -1.35 | -1.35 | 0.236 | 2.38 | 0.0548 | -- | 2.48 | 197,510.60 | -31.70 | -- | -34.39 | -- | -- | -- | -578.80 | -- | -- | -- | 0.1948 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Rapt Therapeutics Inc | 0.00 | -120.43m | 100.87m | 122.00 | -- | 0.9236 | -- | -- | -3.12 | -3.12 | 0.00 | 3.13 | 0.00 | -- | -- | 0.00 | -69.23 | -46.30 | -75.81 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| Genelux Corp | 8.00k | -26.54m | 101.19m | 23.00 | -- | 2.65 | -- | 12,648.62 | -0.9704 | -0.9704 | 0.0003 | 1.11 | 0.0002 | -- | -- | 347.83 | -69.34 | -- | -84.43 | -- | -- | -- | -331,725.00 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
| Bioatla Inc | 0.00 | -104.56m | 101.51m | 65.00 | -- | 3.24 | -- | -- | -2.18 | -2.18 | 0.00 | 0.6491 | 0.00 | -- | -- | 0.00 | -84.23 | -48.72 | -106.06 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
| Renovaro Inc | 0.00 | -80.65m | 102.53m | 25.00 | -- | 0.7447 | -- | -- | -0.7942 | -0.7942 | 0.00 | 0.8513 | 0.00 | -- | -- | 0.00 | -72.84 | -39.86 | -89.56 | -42.11 | -- | -- | -- | -- | -- | -10.76 | 0.0182 | -- | -- | -- | -103.23 | -- | -37.12 | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -17.69m | 102.91m | 9.00 | -- | 17.32 | -- | -- | -0.1726 | -0.1726 | 0.00 | 0.0537 | 0.00 | -- | -- | 0.00 | -91.52 | -58.16 | -138.98 | -75.36 | -- | -- | -- | -- | -- | -- | 0.0427 | -- | -- | -- | -14.90 | -- | -- | -- |
| CervoMed Inc | 9.65m | -5.04m | 103.50m | 8.00 | -- | 2.07 | -- | 10.72 | -0.4796 | -0.4796 | 1.55 | 6.06 | 0.2803 | -- | -- | 1,206,660.00 | -14.64 | -53.67 | -15.71 | -58.89 | -- | -- | -52.24 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| Cue Biopharma Inc | 8.30m | -46.96m | 103.56m | 53.00 | -- | 3.87 | -- | 12.48 | -0.9743 | -0.9743 | 0.1718 | 0.4445 | 0.1437 | -- | 5.56 | 156,528.30 | -81.32 | -57.45 | -113.52 | -68.41 | -- | -- | -566.02 | -810.87 | -- | -- | 0.2242 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
| X4 Pharmaceuticals Inc | 563.00k | 17.63m | 104.05m | 93.00 | 7.21 | 1.10 | 5.76 | 184.81 | 0.0857 | 0.0857 | 0.0028 | 0.5616 | 0.0029 | -- | 0.6726 | 6,053.76 | 9.18 | -61.53 | 10.59 | -69.20 | 52.40 | -- | 3,131.79 | -13,288.93 | 6.04 | -- | 0.4427 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -48.41m | 105.47m | 47.00 | -- | 3.30 | -- | -- | -1.01 | -1.01 | 0.00 | 0.6003 | 0.00 | -- | -- | 0.00 | -51.98 | -48.44 | -55.36 | -51.56 | -- | -- | -- | -1,267.25 | -- | -- | 0.6171 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Immunic Inc | 0.00 | -95.31m | 106.29m | 77.00 | -- | 1.67 | -- | -- | -1.51 | -1.51 | 0.00 | 0.7058 | 0.00 | -- | -- | 0.00 | -108.78 | -72.09 | -141.92 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
| Assembly Biosciences Inc | 21.48m | -45.61m | 106.48m | 65.00 | -- | 3.07 | -- | 4.96 | -9.32 | -9.32 | 4.28 | 5.47 | 0.2362 | -- | 125.62 | 330,476.90 | -50.15 | -39.69 | -69.22 | -44.03 | -- | -- | -212.33 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
| Annovis Bio Inc | 0.00 | -43.02m | 106.52m | 6.00 | -- | -- | -- | -- | -4.42 | -4.42 | 0.00 | -0.1494 | 0.00 | -- | -- | 0.00 | -308.78 | -106.31 | -395.89 | -124.71 | -- | -- | -- | -- | -- | -51.53 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
| Adicet Bio Inc | 0.00 | -117.88m | 107.95m | 143.00 | -- | 0.5103 | -- | -- | -1.70 | -1.70 | 0.00 | 2.57 | 0.00 | -- | -- | 0.00 | -49.20 | -37.03 | -53.58 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
Data as of Nov 08 2024. Currency figures normalised to CervoMed Inc's reporting currency: US Dollar USD
37.48%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Jun 2024 | 817.12k | 9.90% |
| Armistice Capital LLCas of 30 Jun 2024 | 640.00k | 7.75% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 399.45k | 4.84% |
| AWM Investment Co., Inc.as of 30 Jun 2024 | 314.04k | 3.81% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 276.74k | 3.35% |
| Ikarian Capital LLCas of 30 Jun 2024 | 237.35k | 2.88% |
| Soleus Capital Management LP (Investment Management)as of 30 Jun 2024 | 126.61k | 1.53% |
| Geode Capital Management LLCas of 30 Jun 2024 | 100.89k | 1.22% |
| Crown Advisors Management, Inc.as of 30 Jun 2024 | 100.00k | 1.21% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 81.55k | 0.99% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
